Zeyu Bi1, Ling Wang1, Huixin Hou1, Miao Lu1, Wei Wang2, Zishuo Li2, Chengjiang Liu3. 1. Hubei Key Laboratory of Environmental and Health Effects of Persistent Toxic Substances, School of Environment and Health, Jianghan University, Wuhan, China. 2. Department of outpatients, Wuhan Asian Heart Hospital, Wuhan, China. 3. Department of Gastroenterology, Anhui Medical University, Hefei, China.
Abstract
Background: Chronic hepatitis B (CHB) affects a vast population globally. A variety of drugs are available for the treatment of CHB, including tenofovir (TDF) and adefovir (ADV). However, the efficacy of monotherapy drug treatment is inconclusive, the safety and efficacy of TDF remain unclear, more data are needed to be included and combined drug treatment is considered to exhibit higher efficacy. To explore this issue, we performed a current literature review and meta-analysis to compare the efficacy and safety of ADV vs. TDF, TDF vs. ADV + lamivudine (LAM); TDF vs. ADV + entecavir (ETV). Methods: We systematically searched China National Knowledge Infrastructure, the Cochrane Library, Embase, PubMed, Chinese VIP, and Wanfang Data, for relevant clinical trials since July 2015, all included studies were based on PICOS principles and evaluated independently by the reviewers in accordance with the Cochrane Handbook (Rob2.0). A meta-analysis was performed by using Review Manager 5.4. Results: We included a total of 32 studies, including 31 randomized controlled trials and one retrospective study involving 2,473 patients. The results revealed a low risk of bias in included studies, that the virologic response of TDF was superior to ADV (P<0.05). And TDF was also superior to ADV in Serum creatinine levels, Immunologic function, and safety profile. However, when ADV was combined with other medications, it was superior to TDF in alanine aminotransferase (ALT) level and Tbil level and adverse reactions, but on other indicators, TDF was superior to drug combination therapy. Conclusions: Results showed that TDF was superior to ADV in the parameters of ALT, hepatitis B virus (HBV)-DNA reduction, HBeAg-negative conversion rate, safety, and total bilirubin levels in patients with CHB. However, when ADV was combined with LAM or ETV, they often showed the same therapeutic effect as TDF in parameters such as ALT level and Tbil level and combined therapy can effectively reduce the occurrence of adverse reactions. In this study, because the sample source countries were limited, a greater number of global studies are needed in the future to verify the current findings. 2022 Annals of Translational Medicine. All rights reserved.
Background: Chronic hepatitis B (CHB) affects a vast population globally. A variety of drugs are available for the treatment of CHB, including tenofovir (TDF) and adefovir (ADV). However, the efficacy of monotherapy drug treatment is inconclusive, the safety and efficacy of TDF remain unclear, more data are needed to be included and combined drug treatment is considered to exhibit higher efficacy. To explore this issue, we performed a current literature review and meta-analysis to compare the efficacy and safety of ADV vs. TDF, TDF vs. ADV + lamivudine (LAM); TDF vs. ADV + entecavir (ETV). Methods: We systematically searched China National Knowledge Infrastructure, the Cochrane Library, Embase, PubMed, Chinese VIP, and Wanfang Data, for relevant clinical trials since July 2015, all included studies were based on PICOS principles and evaluated independently by the reviewers in accordance with the Cochrane Handbook (Rob2.0). A meta-analysis was performed by using Review Manager 5.4. Results: We included a total of 32 studies, including 31 randomized controlled trials and one retrospective study involving 2,473 patients. The results revealed a low risk of bias in included studies, that the virologic response of TDF was superior to ADV (P<0.05). And TDF was also superior to ADV in Serum creatinine levels, Immunologic function, and safety profile. However, when ADV was combined with other medications, it was superior to TDF in alanine aminotransferase (ALT) level and Tbil level and adverse reactions, but on other indicators, TDF was superior to drug combination therapy. Conclusions: Results showed that TDF was superior to ADV in the parameters of ALT, hepatitis B virus (HBV)-DNA reduction, HBeAg-negative conversion rate, safety, and total bilirubin levels in patients with CHB. However, when ADV was combined with LAM or ETV, they often showed the same therapeutic effect as TDF in parameters such as ALT level and Tbil level and combined therapy can effectively reduce the occurrence of adverse reactions. In this study, because the sample source countries were limited, a greater number of global studies are needed in the future to verify the current findings. 2022 Annals of Translational Medicine. All rights reserved.
Entities:
Keywords:
Adefovir (ADV); chronic hepatitis B (CHB); drug combination; meta-analysis; tenofovir (TDF)
Authors: George V Papatheodoridis; George N Dalekos; Ramazan Idilman; Vana Sypsa; Florian Van Boemmel; Maria Buti; Jose Luis Calleja; John Goulis; Spilios Manolakopoulos; Alessandro Loglio; Margarita Papatheodoridi; Nikolaos Gatselis; Rhea Veelken; Marta Lopez-Gomez; Bettina E Hansen; Savvoula Savvidou; Anastasia Kourikou; John Vlachogiannakos; Kostas Galanis; Cihan Yurdaydin; Rafael Esteban; Harry L A Janssen; Thomas Berg; Pietro Lampertico Journal: J Hepatol Date: 2020-06-16 Impact factor: 25.083
Authors: Sae Hwan Lee; Gab Jin Cheon; Hong Soo Kim; Sang Gyune Kim; Young Seok Kim; Soung Won Jeong; Jae Young Jang; Boo Sung Kim; Baek Gyu Jun; Young Don Kim; Dae Won Jun; Joo Hyun Sohn; Tae Yeob Kim; Byung Seok Lee Journal: Antivir Ther Date: 2018
Authors: Manuel Rodríguez; Juan Manuel Pascasio; Enrique Fraga; Javier Fuentes; Martín Prieto; Gloria Sánchez-Antolín; José Luis Calleja; Esther Molina; María Luisa García-Buey; María Ángeles Blanco; Javier Salmerón; María Lucía Bonet; José Antonio Pons; José Manuel González; Miguel Ángel Casado; Francisco Jorquera Journal: World J Gastroenterol Date: 2017-11-07 Impact factor: 5.742